Drug Trial Radar · NCT00141102
Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
Last checked: Nov 19, 2026Latest source record: Mar 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,484
Actual
Start
Oct 2005
Primary completion
May 2009
Study completion May 2009
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 1, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis and/or rheumatoid arthritis.
Conditions
- Osteoarthritis
- Arthritis, Rheumatoid
Interventions
CelecoxibDrug
Participants are assigned to one of two groups in parallel for the duration of the study
Diclofenac + OmeprazoleDrug
Participants are assigned to one of two groups in parallel for the duration of the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)Time frame: 6 month treatment duration
Locations
194 sites in 32 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Genk, Belgium
Pfizer Investigational Site
Ghent, Belgium
Pfizer Investigational Site
Hasselt, Belgium
Pfizer Investigational Site
Liège, Belgium
Pfizer Investigational Site
Goiânia, Goiás, Brazil
Pfizer Investigational Site
Goiânia, Goiás, Brazil
Pfizer Investigational Site
Curitiba, Paraná, Brazil
Pfizer Investigational Site
Curitiba, Paraná, Brazil
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
St. John's, Newfoundland and Labrador, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Newmarket, Ontario, Canada
Pfizer Investigational Site
Windsor, Ontario, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Ste Foy, Quebec, Canada
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Shanghai, China
Pfizer Investigational Site
Shanghai, China
Pfizer Investigational Site
Tianjin, China
Pfizer Investigational Site
Tianjin, China
Pfizer Investigational Site
Guangzhou, Guangdong, China
Pfizer Investigational Site
Nanjing, Jiangsu, China
Pfizer Investigational Site
Chengdu, Sichuan, China
Pfizer Investigational Site
Medellín, Antioquia, Colombia
Pfizer Investigational Site
Barranquilla, Atlántico, Colombia
Pfizer Investigational Site
Barranquilla, Atlántico, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Floridablanca, Santander Department, Colombia
Pfizer Investigational Site
Cartago, Costa Rica
Pfizer Investigational Site
Heredia, Costa Rica
Pfizer Investigational Site
San José, Costa Rica
Showing 40 of 194 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.